selected publications
- T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. Blood. 2024 Academic Article GET IT
- Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial. Seminars in hematology. 2024 Editorial Article GET IT
- Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing. STAR protocols. 2023 Academic Article GET IT
- Mitochondrial DNA Mutations as Natural Barcodes for Lineage Tracing of Murine Tumor Models. Cancer research. 2023 Academic Article GET IT
- Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. Blood advances. 2022 Academic Article GET IT
- In vivo modeling of CLL transformation to Richter's syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities. Blood cancer discovery. 2022 Academic Article GET IT
- Understanding CLL biology through mouse models of human genetics. Blood. 2021 Review GET IT
-
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia.
Cancer research.
2021
Academic Article
GET IT
Times cited: 12 -
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.
Cancer cell.
2021
Academic Article
GET IT
Times cited: 24 -
High throughput single-cell detection of multiplex CRISPR-edited gene modifications.
Genome biology.
2020
Academic Article
GET IT
Times cited: 17 -
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Leukemia.
2020
Academic Article
GET IT
Times cited: 20 -
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
Leukemia.
2019
Academic Article
GET IT
Times cited: 18 -
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Cancer cell.
2019
Academic Article
GET IT
Times cited: 211 -
SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer.
Cancer immunology research.
2019
Academic Article
GET IT
Times cited: 19 -
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Cancer cell.
2019
Academic Article
GET IT
Times cited: 58 -
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Leukemia.
2018
Review
GET IT
Times cited: 38 -
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
JCI insight.
2018
Academic Article
GET IT
Times cited: 38 -
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
The Journal of experimental medicine.
2018
Academic Article
GET IT
Times cited: 61 -
SnapShot: Chronic Lymphocytic Leukemia.
Cancer cell.
2017
Academic Article
GET IT
Times cited: 9 -
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.
Haematologica.
2017
Letter
GET IT
Times cited: 10 -
HSP90, a chaperone that can make you SYK.
Blood.
2017
Comment
GET IT
Times cited: 1 -
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Oncotarget.
2016
Academic Article
GET IT
Times cited: 84 -
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
Journal of immunology (Baltimore, Md. : 1950).
2016
Academic Article
GET IT
Times cited: 32 -
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Leukemia.
2016
Academic Article
GET IT
Times cited: 57 -
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.
Blood.
2016
Academic Article
GET IT
Times cited: 48 -
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 26 -
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Biochimica et biophysica acta.
2015
Review
GET IT
Times cited: 182 -
Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
Pharmacology & therapeutics.
2014
Review
GET IT
Times cited: 47 -
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
Nature medicine.
2014
Academic Article
GET IT
Times cited: 245 -
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013
Review
GET IT
Times cited: 72 -
Targeting B-cell anergy in chronic lymphocytic leukemia.
Blood.
2013
Academic Article
GET IT
Times cited: 64 -
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
Blood.
2013
Academic Article
GET IT
Times cited: 45 -
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.
Leukemia.
2012
Review
GET IT
Times cited: 33 -
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.
Leukemia.
2011
Academic Article
GET IT
Times cited: 33 -
How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection.
Leukemia & lymphoma.
2010
Academic Article
GET IT
Times cited: 14 -
HS1 has a central role in the trafficking and homing of leukemic B cells.
Blood.
2010
Academic Article
GET IT
Times cited: 67